Ditchcarbon
  • Contact
  1. Organizations
  2. Novartis
Public Profile
Pharmaceutical Preparation Manufacturing
CH
updated 18 days ago

Novartis

Company website

Novartis AG, a leading global healthcare company headquartered in Switzerland (CH), has established itself as a pioneer in the pharmaceutical industry since its founding in 1996. With a strong presence in key operational regions including North America, Europe, and Asia, Novartis focuses on innovative medicines, generics, and eye care products. The company is renowned for its commitment to research and development, producing unique therapies in areas such as oncology, cardiology, and immunology. Notable achievements include the development of groundbreaking treatments that have transformed patient care. As a top player in the pharmaceutical market, Novartis continues to drive advancements in healthcare, making significant contributions to global health and well-being.

DitchCarbon Score

How does Novartis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

100

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

33

Industry Benchmark

Novartis's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

100%

Let us know if this data was useful to you

Novartis's reported carbon emissions

In 2024, Novartis reported total carbon emissions of approximately 4,587,300,000 kg CO2e, with Scope 1 emissions at about 207,000,000 kg CO2e, Scope 2 emissions (market-based) at approximately 30,000,000 kg CO2e, and Scope 3 emissions reaching about 4,350,300,000 kg CO2e. This reflects a significant commitment to reducing their carbon footprint, with a target to achieve carbon neutrality in their own operations (Scope 1 and 2) by 2025. Novartis aims to reduce absolute Scope 1 and 2 GHG emissions by 90% from a 2022 baseline by 2030, while also targeting a 42% reduction in absolute Scope 3 emissions within the same timeframe. Furthermore, the company has set a long-term goal to achieve net-zero emissions across its entire value chain by 2040. In recent years, Novartis has made notable progress, achieving a 63% reduction in Scope 1 and 2 emissions compared to their 2016 baseline by 2023. Their climate commitments are aligned with the Science Based Targets initiative (SBTi), which includes a near-term target of reducing overall emissions by 35% by 2030 from a 2016 base year. These initiatives underscore Novartis's dedication to sustainability and its role in addressing climate change, with a focus on both operational efficiency and broader environmental impact.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201020112012201320142015201620172018201920202021202220232024
Scope 1
583,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
922,000,000
0,000,000,000
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
Scope 3
-
-
000,000,000
000,000,000
000,000,000
000,000,000
-
000,000,000
000,000,000
000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Novartis's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Novartis is in CH, which has a very high grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Novartis is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Johnson And Johnson

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Takeda

JP
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Intas

IN
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Bayer

DE
•
Chemicals nec
Updated 14 days ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251018.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy